Pretty good interview. NP clearly explains some t

Pretty good interview. NP clearly explains some things in more detail that were pieced together previously such as the FDA safety data requirements and the last two parts for the BLA filing. I'm curious why they haven't submitted the 525 vs 700 question to the FDA sooner? NP mentioned they expect to send today or tomorrow for decision and if 525 is approved the final part of the BLA could be submitted in la September or early October. With this decision being the bottleneck to approval, I would think they would expedite for a decision. Maybe there was other discussions or decisions required before this could be finalized, but nonetheless a little frustrating as the 525 data was publicly announced 6 May 2019 (2.5 months ago).

Please do your own due diligence. All my posts and comments are not to be considered investment advice.